Thyroid Imaging, Cytology, and Molecular Markers: From Nodule to Diagnosis — A Clinician's Master Guide

Dr Neeraj Manikath , claude.ai

Review Article | Internal Medicine & Endocrinology

Targeted at Postgraduate Trainees (Residents/Registrars) and Practicing Consultants

Author Note: This article synthesises current evidence from major society guidelines (ATA 2015, ACR TI-RADS 2017, BTA 2023), landmark trials, and the accumulated wisdom of bedside endocrinology practice. It is written in the spirit of a grand round — rigorous in evidence, but alive with clinical reasoning.

Opening Vignette: The Nodule That Wasn't "Just a Cyst"

A 38-year-old schoolteacher presented for a routine health check. She had no symptoms referable to the thyroid — no dysphagia, no voice change, no weight loss. Her TSH was 1.8 mIU/L — textbook normal. An incidentally detected 1.8 cm thyroid nodule on a neck ultrasound done for cervical lymphadenopathy was reported as "a simple cyst, no further workup needed." Eighteen months later, she returned with a firm, fixed nodule and an ipsilateral Level III lymph node. Final histology: papillary thyroid carcinoma, tall cell variant, with nodal metastases.

The original ultrasound, in retrospect, had shown a 1.8 cm hypoechoic lesion with a thin peripheral vascularity and an internal echogenic focus — a radiological signature that demanded fine-needle aspiration cytology (FNAC), not reassurance.

This case encapsulates everything that is wrong — and correctable — about how thyroid nodules are evaluated in routine clinical practice. Thyroid nodules are extraordinarily common: prevalence by palpation is 4–7%, but by ultrasound, it exceeds 67% in the general population. The challenge is not finding them. The challenge is knowing what to do when you find one.

Epidemiology and the Clinical Imperative

Thyroid cancer is the most common endocrine malignancy, with an estimated 586,000 new cases globally in 2020 (Global Cancer Observatory). Its incidence has tripled over the past three decades — largely, though not entirely, due to surveillance-driven detection. Critically, fewer than 5–10% of all palpable nodules are malignant — yet distinguishing that minority from the benign majority demands a structured, algorithmic, and evidence-based approach.

The clinician's toolkit in 2024 comprises three interlocking pillars:

Ultrasonography (USG) — risk-stratification and biopsy guidance
Fine-Needle Aspiration Cytology (FNAC) — tissue diagnosis
Molecular Markers — resolving cytological indeterminate cases

Master each pillar, and you will rarely miss a thyroid cancer — or over-treat a benign nodule.

Clinically Relevant Pathophysiology

Understanding why imaging and cytology behave as they do requires a working knowledge of thyroid tumour biology — no more, no less.

Papillary thyroid carcinoma (PTC) accounts for ~85% of all thyroid malignancies. Its signature molecular driver is the BRAF V600E mutation (present in 40–70% of cases), which constitutes the canonical RAS–RAF–MAPK oncogenic pathway activation. This mutation correlates with aggressive histological variants (tall cell, columnar cell), extrathyroidal extension, and reduced radioiodine avidity.

Follicular thyroid carcinoma (FTC) is driven predominantly by RAS mutations and PAX8/PPARγ rearrangements. Unlike PTC, FTC spreads haematogenously — which is why you encounter the paradox of a well-differentiated follicular carcinoma presenting with a solitary bone metastasis before the thyroid lesion is even biopsied.

Poorly differentiated and anaplastic carcinomas harbour secondary mutations in TP53, TERT promoter, and PIK3CA, which explain their loss of differentiation and their resistance to conventional therapies.

Pathophysiology Pearl: The TERT promoter mutation — found in ~10% of differentiated thyroid cancers — is an independent predictor of recurrence and cancer-specific mortality. When present alongside BRAF V600E, the synergy creates a particularly aggressive tumour phenotype. This is why molecular markers are no longer a luxury but a diagnostic necessity.

Section 1: Thyroid Ultrasonography — The First and Most Critical Gate

The Reporting Systems You Must Know

No practicing clinician in 2024 should be requesting a "thyroid USG" without specifying that it be reported using a validated risk-stratification system. Two systems dominate contemporary practice:

1. ACR TI-RADS (Thyroid Imaging Reporting and Data System) Introduced by the American College of Radiology in 2017, TI-RADS assigns points across five feature categories:

Composition (cystic = 0; spongiform = 0; mixed = 1; solid = 2)
Echogenicity (anechoic = 0; hyperechoic/isoechoic = 1; hypoechoic = 2; markedly hypoechoic = 3)
Shape (wider than tall = 0; taller than wide = 3)
Margin (smooth/ill-defined = 0; lobulated/irregular = 2; extrathyroidal extension = 3)
Echogenic foci (none = 0; comet-tail = 0; macrocalcifications = 1; peripheral/eggshell = 2; punctate = 3)

Points are summed to generate TR1–TR5 categories, guiding biopsy thresholds.

2. ATA 2015 Guidelines The American Thyroid Association uses a pattern-based approach (benign/very low/low/intermediate/high suspicion) with defined size thresholds for FNAC.

Clinical Hack ⚡: When you receive a sonography report that does not use TI-RADS or ATA classification, do not accept it at face value. Call the radiologist. A report that says "complex nodule — clinical correlation advised" is an abdication of radiological responsibility, not a diagnosis.

High-Yield Ultrasound Features: Separating Signal from Noise

Feature	Malignancy Risk	LR+
Taller-than-wide shape	High	2.7
Marked hypoechogenicity	High	2.1
Irregular/spiculated margins	High	2.2
Microcalcifications (punctate echogenic foci)	High	2.5
Extrathyroidal extension	Very High	—
Spongiform appearance	Very Low	0.01
Pure cyst	Essentially benign	0.01
Peripheral vascularity	Low-moderate	1.3
Central vascularity	Moderate	1.5

🪙 Clinical Pearl: The "Taller Than Wide" Sign

A nodule whose anteroposterior diameter exceeds its transverse diameter on transverse view (taller-than-wide) is one of the most specific ultrasound features of malignancy, with a specificity of ~93%. It reflects a tumour growing against normal tissue planes rather than along them. Do not dismiss it because the nodule is small. A 7 mm taller-than-wide, markedly hypoechoic nodule with punctate calcifications should be biopsied — despite falling below most size thresholds.

🦪 Oyster: The Spongiform Nodule Masquerade

A spongiform nodule — defined as one composed of >50% microcystic spaces, resembling a wet sponge — has a malignancy risk of less than 0.3% and is given a TI-RADS 2 (benign) classification. It requires no biopsy regardless of size. Many clinicians, seeing a "complex" nodule with multiple small cysts, instinctively biopsy — yet this pattern is the ultrasound signature of adenomatoid nodular goitre, not carcinoma. Recognising this saves the patient an unnecessary procedure.

🦪 Oyster: The Comet-Tail Artefact vs. Microcalcification

These two are frequently confused with potentially serious consequences. Comet-tail artefacts are triangular, bright, reverberation echoes arising from colloid crystals within cystic spaces — they are benign and warrant no additional points in TI-RADS. Punctate echogenic foci without comet tails, located within a solid component, represent psammoma bodies — the crystallised calcifications of papillary thyroid carcinoma — and are highly suspicious. The distinction requires a skilled radiologist and should be explicitly noted in the report.

Lymph Node Assessment: The Undervalued Dimension

When evaluating a thyroid nodule, always assess the central and lateral neck compartments. Features of metastatic lymphadenopathy include:

Loss of fatty hilum
Round shape (rather than ovoid)
Cystic changes within a node — virtually pathognomonic of PTC metastasis
Punctate calcifications within a node
Peripheral vascularity on Doppler

Clinical Pearl 🪙: A lateral neck lymph node with cystic change in a patient with a thyroid nodule is papillary thyroid carcinoma until proven otherwise, even if the thyroid nodule itself appears low-risk. The lymph node cyst is often the first and most dramatic evidence of occult malignancy.

Section 2: Fine-Needle Aspiration Cytology — The Art and Science of the Needle

The Bethesda System: Your Lingua Franca

All thyroid FNA results should be reported using the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), now in its third edition (2023). This six-tier classification anchors management decisions to malignancy risk.

Bethesda Category	Terminology	Malignancy Risk (2023)	Management
I	Non-diagnostic/Unsatisfactory	5–10%	Repeat FNAC (with US guidance)
II	Benign	0–3%	Clinical follow-up
III	AUS/FLUS	10–30%	Repeat FNAC or molecular testing
IV	FN/SFN	25–40%	Molecular testing or surgery
V	Suspicious for malignancy	50–75%	Near-total thyroidectomy
VI	Malignant	97–99%	Near-total thyroidectomy

AUS = Atypia of Undetermined Significance; FLUS = Follicular Lesion of Undetermined Significance; FN = Follicular Neoplasm; SFN = Suspicious for Follicular Neoplasm

Management Hack ⚡: A Bethesda I (non-diagnostic) result is not a benign result — it is an inadequate result. The nodule must be re-biopsied, ideally with ultrasound guidance and an on-site cytopathologist or rapid on-site evaluation (ROSE) to confirm adequacy. If two consecutive FNAs are non-diagnostic, the clinical and ultrasound features must drive the decision — many such nodules ultimately require diagnostic surgery.

Performing the Perfect FNAC: Technique Matters

The yield of a thyroid FNAC is inseparable from technique. The key elements are:

Ultrasound guidance reduces non-diagnostic rates from 15–20% (palpation-guided) to under 5%
25–27 gauge needle is preferred — adequate cellular yield with less haematic contamination
Fanning technique (redirecting the needle within the nodule in a fan pattern) samples different regions and avoids geographic miss
Aspirate the solid component of mixed cystic–solid nodules — the cystic fluid itself has negligible diagnostic yield
Targeting the wall nodule (mural nodule) in predominantly cystic lesions is critical

Clinical Pearl 🪙: For large (>4 cm) nodules, biopsy the peripheral solid rim, not the centre — central necrosis renders central aspirates acellular and non-diagnostic. Similarly, in nodules with calcifications, biopsy around the calcifications rather than targeting them directly, as shadowing makes needle visualisation difficult.

The Bethesda III Conundrum: Navigating Indeterminate Cytology

Bethesda III — Atypia of Undetermined Significance (AUS/FLUS) — is the most clinically vexing category. It should constitute no more than 7–10% of all FNAC reports; a laboratory reporting >10% AUS has quality concerns. The clinical response options include:

Repeat FNAC — upgrades or downgrades ~30% of cases; cannot be performed within 3 months of the original biopsy
Molecular testing — preferred route in contemporary practice
Diagnostic hemithyroidectomy — acceptable if molecular testing is unavailable or the patient prefers definitive surgery

Diagnostic Nuance: A nodule with two consecutive AUS results carries a significantly higher malignancy risk than a single AUS — approaching 30–40% in some series. Do not reassure and discharge these patients; they warrant either molecular profiling or surgical referral.

Section 3: Molecular Markers — The Third Pillar

Why Molecular Testing Has Changed Everything

Before molecular testing, a Bethesda III or IV result almost mandated diagnostic surgery — exposing patients to the risks of thyroidectomy for what turned out to be benign disease in 60–75% of cases. Molecular testing has fundamentally altered this calculus.

Two platforms dominate current practice:

1. Afirma Gene Sequencing Classifier (GSC) — The "Rule-Out" Test

The Afirma GSC analyses 511 gene expression profiles from FNAC material and classifies nodules as "Suspicious" or "Benign."

Negative predictive value (NPV): 95–96% — a "Benign" result effectively rules out malignancy
Sensitivity: ~91% | Specificity: ~68%
Ideal use: Bethesda III and IV nodules, where a "Benign" result avoids surgery
An "Afirma-Benign" Bethesda IV nodule has a malignancy risk equivalent to a Bethesda II — these patients can be safely observed

Oyster 🦪: Afirma performs less well in Hürthle cell neoplasms — it has a high false-suspicious rate in this histological subtype. The Afirma Xpression Atlas (XA) add-on, which sequences for specific mutations and fusions, can refine this assessment. Always check whether your molecular report includes the XA panel when dealing with oncocytic (Hürthle cell) lesions.

2. ThyroSeq v3 Genomic Classifier — The "Rule-In and Rule-Out" Test

ThyroSeq v3 is a next-generation sequencing panel that evaluates 112 genes for mutations, copy number alterations, and gene fusions.

NPV: 97–98% (for Bethesda III/IV nodules)
Sensitivity: ~98% | Specificity: ~82%
Positive predictive value (PPV): ~66%
Unlike Afirma, ThyroSeq provides specific mutational information — a BRAF V600E-positive result predicts PTC, while a RAS mutation in a Bethesda IV nodule predicts follicular-patterned neoplasia (often requiring hemi rather than total thyroidectomy)
Negative result = "ThyroSeq Negative" → malignancy risk reduced to ~3–5% → observation is justified

Clinical Hack ⚡: When a ThyroSeq result returns RAS-mutant in a Bethesda IV nodule, this does not mandate total thyroidectomy. RAS mutations are shared by follicular adenomas, follicular carcinomas, and the follicular variant of PTC. Hemithyroidectomy is appropriate — with completion thyroidectomy only if final histology confirms malignancy with features requiring radioiodine.

3. Other Molecular Markers

BRAF V600E mutational analysis (single-gene): High specificity (~99%) for PTC when positive; low sensitivity (~60%). Useful as a rapid reflex test on FNA material when cytology is suspicious (Bethesda V).
RET/PTC rearrangements: Present in ~20% of PTCs, higher in radiation-associated cases. Detected by FISH or sequencing.
PAX8/PPARγ rearrangements: Diagnostic of follicular thyroid carcinoma and not seen in adenomas; useful when cytology is follicular.
TERT promoter mutations: Not used diagnostically but carry prognostic weight — their co-occurrence with BRAF V600E predicts aggressive disease and recurrence.
miRNA panels: Under investigation; miR-221, miR-222, and miR-146b are upregulated in PTC but not yet clinical practice standard.

The Molecular Marker Decision Tree

Bethesda III / IV
        |
        ├──> Molecular Testing Available?
        |         |
        |         YES
        |         |
        |    Afirma GSC or ThyroSeq v3
        |         |
        |    Benign/Negative ──────────→ Observe (US at 12–24 months)
        |         |
        |    Suspicious/Positive
        |         |
        |    Specific mutation identified?
        |         |
        |    BRAF V600E ────────────→ Total thyroidectomy + central neck dissection
        |    RAS / PAX8-PPARγ ────→ Hemithyroidectomy → await histology
        |    High-risk fusion ─────→ Total thyroidectomy
        |
        NO (molecular unavailable)
        |
        ├──> Bethesda III: Repeat FNAC in 3–6 months
        └──> Bethesda IV: Diagnostic hemithyroidectomy

Section 4: Diagnostic Nuances — What Separates Good from Great

History Red Flags That Should Raise Immediate Suspicion

Rapid nodule growth — malignancy or (more commonly) haemorrhage into a nodule; distinguish with FNAC ± elastography
Voice change (hoarseness) — recurrent laryngeal nerve involvement until proven otherwise; mandates direct laryngoscopy before surgery
Childhood head/neck radiation exposure — lifetime risk of PTC up to 40%; every such patient needs annual surveillance USG
Family history of PTC, MEN 2, familial adenomatous polyposis (FAP), or Cowden syndrome — germline testing and aggressive screening warranted
Male sex + nodule — men have a lower overall prevalence of nodules but a higher per-nodule malignancy risk (~15–20% vs. 5–8% in women)
Dysphagia or compressive symptoms — can be benign (large goitre) but warrants cross-sectional imaging to rule out tracheal/oesophageal involvement

Examination Findings That Clinicians Miss

Delphian node — a single midline pre-laryngeal lymph node; when palpable, strongly suggests central compartment PTC
Pyramidal lobe enlargement — often feels like a separate nodule extending superiorly from the isthmus; often Graves-related but can harbour malignancy
Pemberton's sign — bilateral arm elevation causing facial plethora and venous engorgement from superior vena cava compression by a retrosternal goitre; easily elicitable at the bedside

Oyster 🦪: A firm, non-tender, seemingly "thyroiditis-like" gland can occasionally represent Riedel's thyroiditis (fibrous variant), a rare but critical diagnosis because it causes severe compressive symptoms and is associated with IgG4-related disease. FNAC yields scant cells (fibrosis), and diagnosis requires open biopsy. Clinicians who have not encountered this entity will repeatedly biopsy and be baffled.

Section 5: State-of-the-Art Updates Changing Practice

1. Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP)

In 2016, an international consensus reclassified the encapsulated follicular variant of PTC — previously treated as cancer — as a pre-malignant entity called NIFTP, provided it is non-invasive, encapsulated, and lacks vascular invasion. This has significant implications:

NIFTP does not require radioiodine ablation after hemithyroidectomy
It does not require total thyroidectomy if the contralateral lobe is uninvolved
Cytologically, NIFTP overlaps with AUS and FN categories — which is one reason those Bethesda categories have a non-trivial malignancy risk even after reclassification

Practice-Changing Update: Many "false positive" FNACs in the pre-2016 literature were actually correctly identifying NIFTP, which was misclassified as PTC. Post-2016 Bethesda malignancy risk estimates exclude NIFTP from the numerator; when NIFTP is included, the malignancy risk of Bethesda III–IV is higher than currently cited.

2. Contrast-Enhanced Ultrasound (CEUS) for Thyroid Nodules

CEUS using microbubble agents (SonoVue) demonstrates wash-in/wash-out kinetics that correlate with malignancy. Malignant nodules typically show heterogeneous enhancement with early wash-out, while benign lesions show sustained enhancement. Not yet standard of care, but increasingly used in academic centres to triage indeterminate lesions before molecular testing or surgery.

3. Ultrasound Elastography

Shear-wave elastography measures tissue stiffness. Malignant thyroid nodules are stiffer than benign lesions (higher Young's modulus values). Meta-analytic data show:

Sensitivity: ~83% | Specificity: ~84% for malignancy detection
Current role: adjunct to B-mode USG in indeterminate lesions, not a replacement for FNAC
Strain elastography is operator-dependent; shear-wave elastography is more reproducible

4. Revised BTA Guidelines 2023

The British Thyroid Association's 2023 guidelines introduced the U-classification system (U1–U5) aligned with TI-RADS, emphasising:

Elastography integration into risk scoring
Molecular testing pathway for Bethesda III/IV
Surveillance intervals based on TI-RADS category rather than size alone

Section 6: Management Intricacies

When to Operate — and How Much Thyroid to Remove

The question of hemithyroidectomy vs. total thyroidectomy is nuanced and increasingly individualised:

Total thyroidectomy is indicated when:

Tumour >4 cm
Gross extrathyroidal extension
Clinical or radiological nodal disease (N1)
Distant metastases (M1)
High-risk molecular profile (BRAF V600E + TERT promoter)
Bilateral multifocal disease

Hemithyroidectomy is sufficient when:

Unifocal PTC, 1–4 cm, no extrathyroidal extension, no nodal disease, low-risk molecular profile
Bethesda IV nodule with RAS mutation (diagnostic and potentially curative in one step if histology is benign)

Clinical Hack ⚡: A 1–2 cm PTC with no adverse features can be managed by active surveillance in appropriately selected patients — particularly older patients, those with significant comorbidities, or those who refuse surgery. This approach, pioneered by the Kuma Hospital (Miyakami et al.) and Memorial Sloan Kettering data, shows <2% progression over 10 years. In selected patients, this avoids surgery and lifetime thyroid replacement without meaningfully increasing mortality.

TSH Suppression: Precision Dosing, Not Blanket Suppression

The goal of TSH suppression post-thyroidectomy has been refined:

Risk Category	TSH Target
High-risk (persistent/metastatic disease)	<0.1 mIU/L
Intermediate-risk (post-ablation)	0.1–0.5 mIU/L
Low-risk (excellent response to treatment)	0.5–2.0 mIU/L (normal range)

Chronic TSH suppression below 0.1 mIU/L carries real risks: atrial fibrillation, osteoporosis, and cardiovascular morbidity. These risks are unacceptable in patients with excellent treatment response — a point frequently missed in routine follow-up.

Section 7: When to Escalate / When to Watch

Escalate to Surgery or Oncology When:

Bethesda V or VI with any nodule — near-total thyroidectomy is indicated
Bethesda IV with high-risk molecular profile
Rapid nodule growth (>20% volume increase in 12 months) despite two reassuring FNACs
Compressive symptoms — dysphagia, stridor, orthopnea
Vocal cord palsy on laryngoscopy
Pathological central or lateral neck nodes (even with a low-suspicion nodule — look harder)
Anaplastic thyroid carcinoma (any suspected case) — refer to a multidisciplinary thyroid tumour board within 24–48 hours; this tumour has a median survival of 5 months and requires urgent multimodal therapy

Safe to Watch (Surveillance) When:

Bethesda II with no growth on repeat imaging at 12 months — discontinue further surveillance if stable at 24 months
Bethesda III with "Benign" Afirma or "Negative" ThyroSeq
TI-RADS 2 or 3, no suspicious features, stable over 2 years
<1 cm nodule (microcarcinoma) with no high-risk features — active surveillance is oncologically equivalent to surgery in most patients

Oyster 🦪: The ATA 2023 active surveillance protocol for low-risk microcarcinomas requires clear shared decision-making documentation, not just verbal consent. Patients who choose surveillance must be counselled explicitly about the <5% risk of local progression and the extremely rare risk of nodal spread during the observation period. Document this conversation meticulously — it protects your patient and yourself.

Memorable Summary: The THYROID Mnemonic

For bedside risk assessment of any thyroid nodule:

Letter	Feature	Clinical Action
T	Taller-than-wide shape	Biopsy regardless of size
H	Hypoechogenicity (marked)	Adds TI-RADS points; indicates FNAC
Y	Young male patient	Higher per-nodule malignancy risk
R	Radiation history / Family history	Lower threshold for biopsy + molecular testing
O	Origin of symptoms (hoarseness, dysphagia)	Urgent ENT + imaging + FNAC
I	Irregular margins / Internal calcifications	High TI-RADS; biopsy mandatory
D	Draining node (cervical LN)	Biopsy the node + thyroid; rule out metastasis

References

Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017;14(5):587–595.
Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017;27(11):1341–1346.
Bongiovanni M, Spitale A, Faquin WC, et al. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol. 2012;56(4):333–339.
Nikiforova MN, Mercurio S, Wald AI, et al. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer. 2018;124(8):1682–1690.
Steward DL, Carty SE, Sippel RS, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study. JAMA Oncol. 2019;5(2):204–212.
Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumours. JAMA Oncol. 2016;2(8):1023–1029.
Ito Y, Miyauchi A, Kihara M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24(1):27–34.
Phuttharak W, Wisitpanich W. Diagnostic performance of shear wave elastography for differentiation of benign and malignant thyroid nodules: a systematic review and meta-analysis. Eur J Radiol. 2020;131:109200.
Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32(25):2718–2726.
Durante C, Grani G, Lamartina L, et al. The diagnosis and management of thyroid nodules: a review. JAMA. 2018;319(9):914–924.
Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules — 2016 update. Endocr Pract. 2016;22(suppl 1):1–60.
Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria, and Explanatory Notes. 3rd ed. Springer; 2023.
Tuttle RM, Fagin JA, Minkowitz G, et al. Natural history and tumour volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg. 2017;143(10):1015–1020.
Lamartina L, Grani G, Biffoni M, et al. Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer. J Clin Endocrinol Metab. 2016;101(8):3036–3044.

Disclosure: The author has no conflicts of interest to declare. No funding was received for the preparation of this article.